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OBJECTIVE—Mutations in the HNF1A gene are the most
common cause of maturity-onset diabetes of the young (MODY).
There is a substantial variation in the age at diabetes diagnosis,
even within families where diabetes is caused by the same
mutation. We investigated the hypothesis that common polygenic
variants that predispose to type 2 diabetes might account for the
difference in age at diagnosis.
RESEARCH DESIGN AND METHODS—Fifteen robustly as-
sociated type 2 diabetes variants were successfully genotyped in
410 individuals from 203 HNF1A-MODY families, from two study
centers in the U.K. and Norway. We assessed their effect on the
age at diagnosis both individually and in a combined genetic
score by summing the number of type 2 diabetes risk alleles
carried by each patient.
RESULTS—We conﬁrmed the effects of environmental and
genetic factors known to modify the age at HNF1A-MODY
diagnosis, namely intrauterine hyperglycemia (5.1 years if
present, P  1.6  10
10) and HNF1A mutation position (5.2
years if at least two isoforms affected, P  1.8  10
2).
Additionally, our data showed strong effects of sex (females
diagnosed 3.0 years earlier, P  6.0  10
4) and age at study (0.3
years later diagnosis per year increase in age, P  4.7  10
38).
There were no strong individual single nucleotide polymorphism
effects; however, in the combined genetic score model, each
additional risk allele was associated with 0.35 years earlier
diabetes diagnosis (P  5.1  10
3).
CONCLUSIONS—We show that type 2 diabetes risk variants of
modest effect sizes reduce the age at diagnosis in HNF1A-MODY.
This is one of the ﬁrst studies to demonstrate that clinical
characteristics of a monogenic disease can be modiﬁed by
common polygenic variants. Diabetes 59:266–271, 2010
M
aturity-onset diabetes of the young (MODY) is
a young-onset, dominantly inherited non–
insulin-dependent diabetes resulting from
-cell dysfunction (1). There are at least eight
genetic subgroups of MODY (1,2), with most patients
having mutations in transcription factor genes. Hepatocyte
nuclear factor 1 (HNF1A) mutations are the commonest
cause of MODY in many series (3,4). HNF1A diabetes is
characterized by progressive failure of -cell function,
resulting in increasing hyperglycemia throughout life (1).
Initially, basal insulin secretion is maintained, but it can-
not be increased in the presence of hyperglycemia (5).
The severity and clinical presentation of MODY varies
according to MODY genetic subtype (6). In addition, there
can be considerable variation both between and within
families where diabetes is caused by mutations in the
same gene. In HNF1A diabetes, the age of diagnosis is
widely variable (4–74 years [7]), and, although the muta-
tions are highly penetrant, only 63% of mutation carriers
develop diabetes by the age of 25 years (8). The variation
in diagnosis is inﬂuenced by social and environmental
factors. Within families, early age at diagnosis tends to fall
in the younger generations, in part owing to increased
awareness of the familial nature of the condition (9,10). If
the mother had diabetes during pregnancy, intrauterine
exposure to hyperglycemia of maternal diabetes is associ-
ated with diabetes being diagnosed, on average, 12 years
earlier compared with subjects not exposed to maternal
hyperglycemia (9,10).
It is likely that there are genetic modiﬁers of the age of
onset of HNF1A diabetes, namely the position of the
HNF1A mutation (11,12). However, much of the variation
in age at diagnosis within families, where diabetes is
caused by the same mutation, cannot be explained by
social or environmental factors, and this supports the
notion that there are likely to be genetic modiﬁers inde-
pendent of the HNF1A mutation. A genome-wide search
for genetic modiﬁers of diagnosis age found no single large
linkage peak (13), suggesting that the age of onset is a
complex genetic trait. A previous study of one large
pedigree has shown that severity of the HNF1A diabetes
phenotype was increased (earlier age of diagnosis and
more severe hyperglycemia) when type 2 diabetes was
present in the noncarrier parent (14). We therefore hy-
pothesized that common genetic variants that predispose
to type 2 diabetes might modify the severity of the disease
and explain some of the variation in the age at HNF1A
diabetes diagnosis.
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HNF1A mutation patients. The subjects were 410 HNF1A mutation carriers
with diabetes from two sources: the Department of Molecular Genetics, Royal
Devon, and Exeter National Health Service Foundation Trust, Exeter, U.K.
(n  298 from 140 families) and the Center for Diabetes Genetics, Department
of Pediatrics, Haukeland University Hospital, Bergen, Norway (n  112 from
63 families). They were all established MODY patients previously recruited for
HNF1A sequencing on the basis of clinical criteria, such as family history or
ﬁrst-degree relative with diabetes, onset of diabetes typically before age 25
years, or low-dose insulin requirement (full details are available at http://www.
diabetesgenes.org and http://www.mody.no).
All patients gave consent for genetic testing and had HNF1A mutations
identiﬁed by direct sequencing. To avoid population heterogeneity, individuals
who were not Caucasian Europeans were excluded. Clinical characteristics of
the patients are shown in Table 1. Two-thirds were female, and the majority of
the probands had an HNF1A mutation in exons 1–6. Such mutations are
regarded as clinically most severe as they affect all three isoforms of the gene
product. The most common HNF1A mutation, P291fsinsC in exon 4, ac-
counted for 32% of all cases in this study.
Classiﬁcation and assessment of nonpolygenic modiﬁers. We assessed
the association between age at diagnosis and the following nonpolygenic
factors: sex, age at study, BMI, exposure to in utero hyperglycemia, and the
position of HNF1A mutation. Mother’s diabetes status at pregnancy was
calculated from the age of diagnosis and the date of birth of the mother and
child. Where this information was incomplete (usually owing to mother’s
information not being available as deceased), we assumed that the patient was
not exposed to in utero hyperglycemia. Previous studies have shown that
mutation position impacts the severity of the disease by determining the
number of the affected HNF1A isoforms: patients with mutations in exons 1–7,
affecting two or all three isoforms, were diagnosed earlier than patients with
mutations in exons 8–10, affecting only one isoform (11,12). To account for
this effect, we classiﬁed mutations of patients in this study according to those
two groups. Intronic mutations were assigned to a group according to the
HNF1A isoform impacted.
Single nucleotide polymorphism selection and genotyping. We decided
to include in this study only those variants, or their proxies, robustly shown to
predispose to type 2 diabetes in Caucasians. Seventeen common susceptibility
variants had been identiﬁed and robustly replicated at the time of our study
(15–20) (recently rev. in 21,22). These include single nucleotide polymophisms
(SNPs) in or near PPARG, KCNJ11, TCF7L2, IGF2BP2, CDKN2A/2B,
CDKAL1, SLC30A8,HHEX/IDE,FTO,WFS1,HNF1B (TCF2), MC4R, NOTCH2,
ADAMTS9, THADA, TSPAN8/LGR5, CDC123/CAMK1D, and JAZF1 genes.
Table 3 lists all 17 SNPs assessed in our study, of which we were able to
combine 15 for the joint analysis, because JAZF1 and NOTCH2 loci failed
genotyping in the Norwegian samples. At 4 of 15 loci, different SNPs were
genotyped by the two study centers: rs757210 (U.K.) and rs4430796 (Norway)
at the HNF1B locus (HapMap CEU r
2  0.61, D0.96), rs10946398 and
rs7754840 at CDKAL1 (r
2 and D1), rs8050136 and rs9939609 at FTO (r
2 and
D1), and rs1111875 and rs5015480 at HHEX/IDE (r
2 and D1). We
combined genotypes for each of the four proxy pairs, coded with respect to
the type 2 diabetes risk allele.
In the U.K. samples, genotyping of TCF7L2, KCNJ11, and PPARG SNPs
was performed in house, using a TaqMan-based assay. The probes were
supplied by Applied Biosystems (Foster City, CA). Genotyping of the remain-
ing 14 variants was performed by K Biosciences (Herts, U.K.), who designed
and used assays based on either their proprietary competitive allele-speciﬁc
PCR (KASPar) method or a modiﬁed TaqMan assay (details of which are
available on their website www.kbioscience.co.uk/chemistry/chemistry_
Kasp_intro.htm). Genotyping success rate was 96% for each SNP, overall
duplicate concordance rate was 99.9% (one discrepancy from 1,153 compari-
sons), and in the Hardy-Weinberg equilibrium test, used as an additional
genotyping quality check, all P values were 0.01 for the full dataset and
0.05 for 140 unrelated probands.
In the Norwegian samples, genotyping was carried out by the multiplex
MassARRAY iPLEX System (Sequenom, San Diego, CA) at the Norwegian
national technology platform CIGENE. NOTCH2 SNP (rs2934381) failed the
assay design, while JAZF1 SNP (rs864745) had a poor genotype call rate. For
the remaining 15 SNPs, which we were able to combine with the U.K. data,
genotype concordance rate was 100% for internal controls (n  108 geno-
types). Final genotyping call rate was 99.2% after exclusion of samples with
bad quality or lacking DNA. All tests for Hardy-Weinberg equilibrium had P
values 0.05.
Statistical methods. We performed family-based association analyses using
the ASSOC program from S.A.G.E. (Statistical Analysis for Genetic Epidemi-
ology) software package, version 5.4.2, for Linux (23). Assuming randomly
sampled independent pedigrees, ASSOC simultaneously tests for associations
between a quantitative trait and one or more covariates of interest and
estimates familial variance components from the given familial correlations.
In our study, the trait of interest was age at diabetes diagnosis, while the
main covariate of interest was the number of type 2 diabetes risk alleles.
As one of the parameters for the ASSOC program, we set the family effect
option to “true,” thus including the random nuclear family effect as an
additional term in the regression model. Relationships between family
members were fully established for most pedigrees. In some of the large
pedigrees, we included parents and relatives that had no data for the
analyses but were used by the program to accurately connect all related
individuals. Singletons and ﬁve U.K. family members for whom we could
not establish how they were related to other members of their pedigrees
were automatically treated as one-person pedigrees and required no
special handling in the model.
We assessed the effect of each risk variant on the age at diagnosis
individually, jointly and by using an allele counting method to assign a genetic
risk score to each patient (the sum of the number of risk alleles a person
carries). The allele-counting method assumed equal and additive effects of the
individual variants. We repeated this analysis using a weighted allele ap-
proach, where the genetic score was based on the previously reported odds
ratios (ORs) for type 2 diabetes (obtained from a recent review [22]). For each
patient, we ﬁrst calculated the sum across SNPs of the number of risk alleles
at each SNP multiplied by the log of the OR for that SNP (i.e., genotypes were
coded as 0, log(OR), or 2xlog(OR), rather than 0, 1, 2 in the allele count
model). To obtain a rescaled “weighted allele count” score, we multiplied each
log(OR) score by 30 (maximum number of risk alleles) and divided the
product by 1.81, the sum of the 15 risk homozygote log(OR) weights.
Although family relationships were fully accounted for in the analyses, it is
possible that the results could have been affected by the skewed allele
distributions. Therefore, we analyzed the effects of both individual SNPs and
the combined genetic score on age at diagnosis in 203 unrelated probands,
using the youngest individual from each pedigree (see supplementary Table 1
in the online appendix [available at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-0555/DC1]).
TABLE 1
Characteristics of the 410 HNF1A-MODY patients included in the analyses
U.K. Norway
Families/singletons 140/87 63/41
Examined individuals 298 112
Male subjects 100 (33.6) 41 (36.6)
Average number of individuals in nonsingleton families
(range) 3.0 (2–9) 3.1 (2–8)
Individuals with HNF1A mutations affecting:
Isoform A only (exons 8–10) 30 3
Isoforms A and B only (exon 7) 22 4
Isoforms A, B, and C (exons 1–6) 246 105
Age at study (years) 37.1  17.0 (8–87) 33.4 	 17.6 (6–73)
Age at diabetes diagnosis (years) 21.9  11.2 (4–70) 20.3 	 10.0 (6–60)
BMI (kg/m
2)* 24.1  4.1 (15.9–50.7) 23.9 	 3.7 (15.8–33.6)
Data are n, n (%), and means  SD (range). *BMI was only available for 224 and 81 individuals in U.K. and Norway studies, respectively.
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TX) to generate adjusted age at diagnosis, using the “predict” function after
running linear regression that ﬁtted family identiﬁcation, study, sex, age at
study, presence of intrauterine hyperglycemia, and mutation position in the
same regression model. This enabled us to use the full dataset, with adjusted
ages at diagnosis, for linear regression and cumulative diabetes incidence
analyses (Figs. 1 and 2), rather than a much smaller sample of unrelated
singletons and phenotypically homogeneous individuals. All ﬁgures were
generated using SigmaPlot (Systat Software, San Jose, CA). Power calcu-
lations were performed using QUANTO power calculator, version 1.2.4
(24).
RESULTS
The analyses included 410 diabetic HNF1A mutation car-
riers from 203 families who were successfully genotyped
for all 15 type 2 diabetes risk variants.
We conﬁrmed the strong effects of age at study, muta-
tion position, and intrauterine hyperglycemia on the sever-
ity of HNF1A diabetes clinical presentation (Table 2).
These associations were independent of the polygenic risk
factors (Table 2). On average, patients were diagnosed 5.1
years earlier if the mother was diabetic during pregnancy
(P  1.6  10
10), 5.2 years earlier if the mutation affected
at least two HNF1A isoforms (P  1.8  10
2), and 0.3
years later for every additional year of their age at study
(P  4.7  10
38). In addition, we observed a strong effect
of sex in our data, where female subjects were diagnosed
3.0 years earlier than male subjects (P  6.0  10
4), but
there was no association with BMI (available for 305
subjects; P  0.99).
We included those variables that had individual effect on
age at diagnosis (i.e., all of the above apart from BMI) as
covariates in the individual and joint SNP models to
reduce the remaining variance in the age at diagnosis and
therefore increase our power to detect the effect of
polygenic modiﬁers. We repeated these analyses excluding
age at study, to make sure that its strong association with
age at diagnosis did not drive the SNP association (sup-
plementary Table 2). As expected, the results were not
statistically signiﬁcantly different to the fully adjusted
model (all t test P  0.32). Although for some of the SNPs
the effects on age at diagnosis were slightly stronger when
age at study was excluded, the SEs were larger, resulting
in similar overall P values.
Individual type 2 diabetes risk variants were not
strongly associated with the age at diagnosis, as shown in
Table 3. However, of 15 variants, 11 risk alleles for type 2
diabetes in the unadjusted analyses and 10 in the adjusted
analyses were associated with reduced age at diagnosis.
When we included all 15 variants in the regression model,
there was borderline evidence of an overall joint effect on
the age at diagnosis (P  0.062). The 15 variants explain
6.4% of the total proportion of age at diagnosis variation,
while the nonpolygenic factors (sex, age at study, muta-
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FIG. 1. Mean age at diabetes diagnosis (Œ) and frequency ()o f
HNF1A-MODY patients at each number of the type 2 diabetes risk
alleles carried. Only individuals genotyped for all 15 variants are
included. A: Full dataset of 410 patients. B: 203 unrelated probands
(youngest family members). Ages at diagnosis were adjusted for family
(A only), study, sex, age at study, exposure to mother’s hyperglycemia
in utero, and position of HNF1A mutation. Black lines are the ﬁtted
age-at-diagnosis linear regression lines. Both y-axes are on the same
scale in A and B.
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FIG. 2. Cumulative incidence of diabetes in 410 HNF1A-MODY patients
by type 2 diabetes risk allele count category. F, 9–14 risk alleles, n 
138; ‚, 15–16 risk alleles, n  130; f, 17–22 risk alleles, n  142. Only
individuals genotyped for all 15 variants are included. The ages at
diabetes diagnosis ware adjusted for family, study, sex, age at study,
exposure to mother’s hyperglycemia in utero, and position of HNF1A
mutation.
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explain 37.9%; combining these together, they explain
42.1% of the total variance in the HNF1A-MODY age at
diagnosis in these families.
We then generated a single genetic risk score represent-
ing the combined genetic susceptibility for type 2 diabetes
(Table 3). In the allele count model, each additional risk
allele was associated with a 0.35-year reduction in age at
diagnosis (P  0.005). The association strength was
weaker when we used unrelated probands (0.28 years
earlier age at diagnosis per one additional risk allele; P 
0.094; supplementary Table 1), which most probably re-
ﬂects reduced power. The correlation between the de-
creasing age at diagnosis and the increasing number of
risk alleles appears to be linear for the full dataset of 410
patients (Fig. 1A). Figure 1B presents the results for 203
unrelated probands only. Looking at the impact of risk
alleles on the cumulative incidence of diabetes, the effect
was most noticeable around age 30 years, where diabetes
developed in 80% of HNF1A mutation carriers with 9–14
polygenic risk alleles, compared with 93% with 17–22 risk
alleles (Fig. 2).
The weighted allele score yielded similar results to the
allele count model (P  0.005). Stratiﬁed analysis showed
that the impact of the allele count score was of similar
magnitude in the two cohorts individually, with all t test P
values 0.1 (supplementary Table 3).
TABLE 2
Results of regression analyses of nonpolygenic factors on the age at diabetes diagnosis in 410 HNF1A-MODY patients with and
without the inclusion of the polygenic risk score in the regression model
Without genetic score With genetic score
Effect size  SE P Effect size  SE P
Study (Norway  0, U.K.  1) 1.31  0.99 0.18 1.44  0.97 0.14
Sex (effect with respect to female subjects) 2.97  0.86 6.0  10
4 2.93  0.85 5.7  10
4
BMI (kg/m
2) (per unit increase)* 0.0009  0.13 0.99 0.033  0.13 0.80
Presence of intrauterine hyperglycemia 5.06  0.79 1.6  10
10 4.86  0.79 6.5  10
10
Position of HNF1A mutation† 5.22  2.21 1.8  10
2 5.67  2.18 9.4  10
3
Age at study (per year increase) 0.29  0.02 4.7  10
38 0.29  0.02 1.5  10
37
All effect sizes are in years. Genetic score is the number of risk alleles, carried by each patient, from the 15 type 2 diabetes susceptibility
variants. *BMI was only available for 305 individuals. †The position of the mutation has been dichotomized into those affecting exons 8–10
(isomer A only; n  33) versus those affecting exons 1–7 (n  377). The age at diagnosis is lower for patients with mutations affecting exons
1–7.
TABLE 3
Effects of individual type 2 diabetes risk variants and the combined genetic scores on the age at diabetes diagnosis in 410
HNF1A-MODY patients
Individual SNP effects
Unadjusted results Adjusted results*
Effect size  SE P Effect size  SE P
Gene region SNP
HNF1B
(TCF2)† rs757210/rs4430796 1.85  0.58 0.0014 1.07  0.43 0.014
SLC30A8 rs13266634 1.07  0.64 0.095 0.90  0.50 0.070
CDKAL1† rs10946398/rs7754840 1.22  0.59 0.038 0.87  0.46 0.059
TCF7L2 rs7903146 0.55  0.63 0.39 0.65  0.46 0.16
ADAMTS9 rs4607103 0.27  0.69 0.70 0.59  0.51 0.25
TSPAN8 rs7961581 0.97  0.63 0.13 0.53  0.44 0.22
JAZF1‡ rs864745 0.45  0.72 0.53 0.46  0.53 0.38
FTO† rs8050136/rs9939609 0.30  0.63 0.63 0.42  0.47 0.37
KCNJ11 rs5219 0.15  0.63 0.82 0.34  0.50 0.50
CDKN2A/2B rs10811661 0.89  0.87 0.31 0.25  0.65 0.70
WFS1 rs10010131 0.08  0.61 0.89 0.21  0.46 0.65
CDC123 rs12779790 0.83  0.75 0.27 0.07  0.55 0.91
HHEX/IDE† rs1111875/rs5015480 0.27  0.61 0.66 0.19  0.44 0.66
PPARG rs1801282 1.46  0.99 0.14 0.36  0.76 0.64
IGF2BP2 rs4402960 0.45  0.64 0.48 0.43  0.47 0.36
THADA rs7578597 0.50  1.00 0.62 0.55  0.78 0.48
NOTCH2‡ rs2934381 1.31  1.32 0.32 0.82  1.00 0.41
Combined SNP effect
Allele count score 0.49  0.17 0.0043 0.35  0.13 0.0051
Weighted score (log odds) 0.49  0.15 0.0013 0.33  0.12 0.0046
All effect sizes are in years change of age at diagnosis per risk allele. The 410 patients were successfully genotyped for all 15 SNPs that were
included in the combined genetic scores. All analyses took into account full family relationships and included a random family effect in the
regression model. Individual SNP effects are based on risk allele count method. P values are unadjusted for multiple testing. Results are
presented in order of the adjusted effect sizes. *Adjusted results include study, sex, age at study, presence of intrauterine hyperglycemia, and
mutation position (two groups, according to exon affected, 1–7 or 8–10) as covariates in the regression model. †At 4 loci different SNPs
representing the same signal were genotyped by the two study centers, in which case they are shown as U.K./Norway SNPs. ‡Results for
JAZF1 and NOTCH2 SNPs were available only for U.K. samples (n  296 and 297, respectively).
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We have shown that type 2 diabetes risk variants of
modest effect sizes when combined are associated with a
reduced age at diagnosis in monogenic HNF1A diabetes.
This association is independent of other genetic and
environmental modiﬁers, namely the HNF1A mutation
position, age at study, sex, and mother’s diabetes status
during pregnancy. Thus, this is one of the ﬁrst studies to
demonstrate that clinical characteristics of a monogenic
disease can be inﬂuenced by common variants that pre-
dispose to the polygenic form of that disease. To our
knowledge, only two other studies, of breast cancer (25)
and Alzheimer’s disease (26) have identiﬁed polygenic
variants that act as modiﬁers of disease onset age.
In support of previous ﬁndings, an increase in the age of
patients at the time of genetic testing is strongly associ-
ated with an older age at diabetes diagnosis. It is not
known if this represents an earlier diagnosis as a result of
the increasing awareness of diabetes in the family by their
physicians or a genuine decrease in age of onset in
succeeding generations. The former is likely to be a large
contributor. In addition, there is strong evidence that the
age at diagnosis is affected by genetic factors. We conﬁrm
previous ﬁndings by Harries et al. (11) and Bellanne ´-
Chantelot et al. (12) that patients with mutations affecting
at least two of the three known HNF1A isoforms were
diagnosed earlier than patients with mutations affecting
only one HNF1A isoform.
In our study, we provide evidence for additional genetic
modiﬁers, the robustly replicated type 2 diabetes risk
variants. Combining the effect of the variants by adding up
the total number of risk alleles carried, each additional
risk allele was associated with 0.49 and 0.35 years earlier
age at diagnosis in the unadjusted and adjusted models,
respectively. Most of the genetic variants predisposing to
type 2 diabetes act through reducing -cell function rather
than increasing insulin resistance. This is true of the three
risk variants with strongest effects observed in this study,
the SNPs in the HNF1B, SLC30A8, and CDKAL1 genes. It
is possible that they interact with the -cell dysfunction
resulting from the HNF1A mutation, leading to an in-
creased rate of -cell destruction and, therefore, earlier
onset of diabetes. Furthermore, mutations of HNF1B, also
known as TCF2, are another known cause of MODY,
accounting for 
2% of cases (27).
This study does have limitations. Although we included
410 subjects, one of the largest cohorts of HNF1A patients
ever reported, some simple power calculations suggest
that we were still underpowered to detect the impact of
individual loci. For example, we had only 29% power to
detect an individual SNP explaining 1% of the variation in
age at diagnosis (and this is assuming independence of the
individuals in the study) at P  0.01; in singleton-only
analysis the power was 13%. These patients were not
studied prospectively, and, therefore, the age at diagnosis
does not accurately reﬂect the age at onset of diabetes. We
would anticipate that if age of onset was studied using
prospective data, the impact of these type 2 diabetes loci
would be greater.
In conclusion, we show that type 2 diabetes risk variants
of modest effect sizes act as an additional modiﬁer of age
at diagnosis in HNF1A-MODY. This is one of the ﬁrst
studies to demonstrate that common variants associated
with a polygenic disease can also inﬂuence clinical char-
acteristics of a monogenic form of the disease.
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